Business & Economy CNBC 1h 20m ago

Biotech takeover target Abivax sinks over 30% after bowel disease drug trial update

Shares of French biotech Abivax tumbled 32% after it reported fresh data on its lead asset.

AI Summary Powered by Happening Now AI

Shares of French biotech Abivax tumbled 32% after it reported fresh data on its lead asset.

AI summaries can be wrong sometimes—always verify important details using the source article.

SUPPORT HAPPENINGNOW · Independent AI News Intelligence

SUPPORTER MESSAGE

Enjoyed this article? Consider supporting HappeningNow to help keep independent AI-powered news analysis moving forward. Your contribution helps cover infrastructure, AI summaries, and continued platform development.

Support HappeningNow